Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Ovid Therapeutics OVID

Healthcare  —  Biotechnology
2.40 (0.10) (4.00%) as of 25 Sep
Market cap
$487.3M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Ovid Therapeutics (OVID) Business Profile

Updated before January 2025

Company Overview

Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical company dedicated to developing innovative therapies for rare neurological disorders. Founded in 2014 by Dr. Jeremy Levin, a seasoned pharmaceutical executive, Ovid is headquartered in New York City, USA. The company’s mission is to bring transformative medicines to patients with unmet medical needs in the field of neurology. Dr. Levin, who serves as the Chairman and CEO, has been instrumental in steering the company’s strategic direction. Other key members of the leadership team include Dr. Amit Rakhit, President and Chief Medical Officer, and Dr. Jeffrey Rona, Chief Financial Officer, who bring extensive experience in drug development and corporate finance.

Core Business Segments

Ovid Therapeutics focuses on the development of therapies targeting rare neurological conditions. Its core business segments include:

1. Neurological Drug Development

Ovid’s primary focus is on developing small-molecule drugs and biologics for rare neurological disorders. Key products and programs include:

  • OV935 (soticlestat): A novel therapy developed in collaboration with Takeda Pharmaceuticals, targeting rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. Soticlestat has shown promising results in clinical trials and is a cornerstone of Ovid’s pipeline.
  • OV882: A preclinical gene therapy program aimed at Angelman syndrome, a rare genetic disorder affecting the nervous system.
  • OV815: A preclinical program targeting KIF1A-associated neurological disorders (KAND), a rare neurodegenerative condition.

2. Collaborative Partnerships

Ovid collaborates with leading pharmaceutical companies and research institutions to accelerate the development of its therapies. The partnership with Takeda Pharmaceuticals for soticlestat is a prime example of its collaborative approach.

3. Research and Development (R&D)

Ovid invests heavily in R&D to identify and develop novel therapies for rare neurological conditions. The company leverages cutting-edge technologies and scientific expertise to advance its pipeline.

Business Model

Ovid Therapeutics operates on a business model centered around innovation, collaboration, and value creation. The company generates revenue primarily through licensing agreements, milestone payments, and royalties from its collaborative partnerships. For instance, its partnership with Takeda Pharmaceuticals includes milestone payments based on the successful development and commercialization of soticlestat.

Ovid’s approach integrates:

  • Drug Development: Focused on rare neurological disorders with high unmet medical needs.
  • Collaborative Partnerships: Leveraging partnerships to share risks and accelerate development timelines.
  • Patient-Centric Approach: Engaging with patient advocacy groups and incorporating patient feedback into its drug development process.

Strategic Direction

Ovid Therapeutics is committed to expanding its pipeline and bringing innovative therapies to market. Key strategic priorities include:

  • Pipeline Expansion: Advancing existing programs such as OV935, OV882, and OV815 while exploring new therapeutic areas within neurology.
  • Global Reach: Expanding its presence in international markets through partnerships and collaborations.
  • Sustainability Goals: Incorporating sustainable practices in its operations and supply chain to minimize environmental impact.
  • Innovation: Investing in cutting-edge technologies such as gene therapy and precision medicine to address complex neurological disorders.

Competitive Landscape

Ovid Therapeutics operates in a competitive biopharmaceutical landscape, with key competitors including:

  • Marinus Pharmaceuticals: Focused on developing therapies for rare epilepsies.
  • Sage Therapeutics: Specializes in treatments for central nervous system (CNS) disorders.
  • Ultragenyx Pharmaceutical: Develops therapies for rare genetic diseases, including neurological conditions.
  • BioMarin Pharmaceutical: A leader in the development of therapies for rare diseases.

Despite the competition, Ovid differentiates itself through its focus on rare neurological disorders and its collaborative approach to drug development.

Risk Factors

Ovid Therapeutics faces several risks, including:

  • Regulatory Risks: The approval process for new drugs is lengthy and uncertain, posing a significant risk to the company’s pipeline.
  • Market Dependence: Ovid’s revenue is heavily dependent on the success of its lead programs, particularly soticlestat.
  • Supply Chain Disruptions: Potential disruptions in the supply chain could impact the production and distribution of its therapies.
  • Competition: Intense competition from other biopharmaceutical companies could affect market share and pricing.
  • Financial Risks: As a clinical-stage company, Ovid relies on external funding and may face challenges in securing additional capital.

Recent Developments

Ovid Therapeutics has made significant progress in recent years, including:

  • Clinical Trials: Advancing soticlestat into late-stage clinical trials for Dravet syndrome and Lennox-Gastaut syndrome.
  • Preclinical Programs: Progressing OV882 and OV815 through preclinical development.
  • Corporate Strategy: Strengthening its leadership team and securing additional funding to support its pipeline.
  • Global Developments: The COVID-19 pandemic posed challenges to clinical trial timelines, but Ovid adapted by implementing remote monitoring and virtual patient engagement strategies.

Investment Considerations

Investors considering Ovid Therapeutics should weigh the following factors:

Strengths:

  • Focus on rare neurological disorders with high unmet medical needs.
  • Strong pipeline with promising clinical and preclinical programs.
  • Collaborative partnerships with industry leaders such as Takeda Pharmaceuticals.
  • Experienced leadership team with a track record of success.

Risks:

  • Dependence on the success of lead programs, particularly soticlestat.
  • Regulatory and clinical trial risks.
  • Financial risks associated with being a clinical-stage company.
  • Competitive pressures from other biopharmaceutical companies.

Conclusion

Ovid Therapeutics is a pioneering biopharmaceutical company with a strong focus on rare neurological disorders. Its innovative pipeline, collaborative approach, and patient-centric philosophy position it as a leader in the field. While the company faces challenges such as regulatory risks and competition, its strategic direction and commitment to innovation provide a solid foundation for future growth. As Ovid continues to advance its pipeline and expand its global reach, it remains a compelling investment opportunity for those seeking exposure to the biopharmaceutical sector.